Spruce Biosciences Competitors

Spruce Biosciences (NASDAQ:SPRB) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and uniQure's revenue, earnings per share and valuation.

Spruce Biosciences has higher earnings, but lower revenue than uniQure.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and uniQure, as reported by MarketBeat.

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. uniQure has a consensus target price of $68.4615, suggesting a potential upside of 106.58%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Spruce Biosciences.

Profitability

This table compares Spruce Biosciences and uniQure's net margins, return on equity and return on assets.

Insider & Institutional Ownership

78.3% of uniQure shares are owned by institutional investors. 2.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

uniQure beats Spruce Biosciences on 6 of the 9 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Heron Therapeutics' revenue, earnings per share and valuation.

Spruce Biosciences has higher earnings, but lower revenue than Heron Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Heron Therapeutics, as reported by MarketBeat.

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Heron Therapeutics has a consensus target price of $29.60, suggesting a potential upside of 81.71%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Heron Therapeutics.

Profitability

This table compares Spruce Biosciences and Heron Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Spruce Biosciences beats Heron Therapeutics on 5 of the 9 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Applied Molecular Transport's revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Applied Molecular Transport, as reported by MarketBeat.

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Applied Molecular Transport has a consensus target price of $68.75, suggesting a potential upside of 63.22%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Applied Molecular Transport.

Profitability

This table compares Spruce Biosciences and Applied Molecular Transport's net margins, return on equity and return on assets.

Insider & Institutional Ownership

52.0% of Applied Molecular Transport shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spruce Biosciences (NASDAQ:SPRB) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Travere Therapeutics' revenue, earnings per share and valuation.

Spruce Biosciences has higher earnings, but lower revenue than Travere Therapeutics.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Travere Therapeutics, as reported by MarketBeat.

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Travere Therapeutics has a consensus target price of $44.3333, suggesting a potential upside of 80.80%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Travere Therapeutics.

Profitability

This table compares Spruce Biosciences and Travere Therapeutics' net margins, return on equity and return on assets.

Summary

Spruce Biosciences beats Travere Therapeutics on 4 of the 6 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares Spruce Biosciences and Supernus Pharmaceuticals' revenue, earnings per share and valuation.

Supernus Pharmaceuticals has higher revenue and earnings than Spruce Biosciences.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Supernus Pharmaceuticals, as reported by MarketBeat.

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Supernus Pharmaceuticals has a consensus target price of $27.6667, suggesting a potential downside of 1.08%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Supernus Pharmaceuticals.

Profitability

This table compares Spruce Biosciences and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Spruce Biosciences on 6 of the 9 factors compared between the two stocks.

Spruce Biosciences (NASDAQ:SPRB) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Insider & Institutional Ownership

63.3% of Generation Bio shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Spruce Biosciences and Generation Bio's revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Spruce Biosciences and Generation Bio, as reported by MarketBeat.

Spruce Biosciences currently has a consensus target price of $33.25, suggesting a potential upside of 106.14%. Generation Bio has a consensus target price of $40.60, suggesting a potential upside of 55.79%. Given Spruce Biosciences' higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Generation Bio.

Profitability

This table compares Spruce Biosciences and Generation Bio's net margins, return on equity and return on assets.

Summary

Generation Bio beats Spruce Biosciences on 2 of the 3 factors compared between the two stocks.